Home / Stocks / Solara Active Pha Sci Ltd
SOLARA

Solara Active Pha Sci Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹640.6

Change

-9.9 (-1.52%)

Open

₹651.3

Prev. Close

₹650.5

Day High

₹651.3

Day Low

₹638.5

Volume Analysis

Traded

71,375

Delivered

38,558

Delivery %

54.02%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (2)

  • •Low return on equity (-0.13%)
  • •Below-average fundamentals quality score (49/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹661.24 ₹656.27 ₹648.44 ₹643.47 ₹635.64 ₹630.67 ₹622.84
Fibonacci ₹656.27 ₹651.38 ₹648.36 ₹643.47 ₹638.58 ₹635.56 ₹630.67
Camarilla ₹644.12 ₹642.95 ₹641.77 ₹643.47 ₹639.43 ₹638.25 ₹637.08

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+13.76%

1 Week

-5.27%

1 Month

-1.18%

3 Months

+3.84%

6 Months

+16.88%

1 Year

+13.77%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

2.31%

Net margin 2.41% × asset turnover 0.56x × equity multiplier 1.71x

Company Overview

Sector

Healthcare

Market Cap

₹3,347 Cr

P/E (TTM)

70.7

ROE

-0.13%

Book Value

₹296.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Solara Active Pha Sci Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (94/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (-0.13%); below-average fundamentals quality score (49/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

94

Growth

0

Valuation

33

Cash Flow

61

Corporate Governance

66

Momentum

76

Institutional Ownership

41

Business Quality

38

Risk & Volatility

58

Liquidity

29

From Screener.in

  • +Company has reduced debt.
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -3.27% over past five years.
  • −Company has a low return on equity of -12.0% over last 3 years.
  • −Promoters have pledged 52.0% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026

Solara Active Pharma Sciences Limited has informed regarding the copy of Newspaper publication informing about Final Reminder-cum-Forfeiture Notice for the payment of First ....

Final reminder for partly paid rights shares: pay ₹131.25 and ₹112.50 by Nov 5, 2026.

Solara Active Pharma Sciences Limited has informed regarding the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....

Crisil report for Q2 FY27 rights issue use shows no deviation; Rs 7.07 crore unutilized.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 425 212 299 363 347 300 273 319 314 349 387 382 417
Expenses + 388 374 290 322 286 243 228 262 279 312 330 320 340
Operating Profit 38 -162 10 42 61 58 45 57 35 37 58 62 77
OPM % 9.0% -76.0% 3.3% 12.0% 18.0% 19.0% 17.0% 18.0% 11.0% 11.0% 15.0% 16.0% 18.0%
Other Income + -4 -62 -120 1 0 1 6 1 0 -7 6 3 -4
Interest 24 25 31 31 28 27 29 24 21 22 28 22 18
Depreciation 26 26 25 25 25 25 24 24 24 26 26 27 27
Profit before tax -17 -275 -167 -13 8 8 -2 11 -10 -17 10 16 28
Tax % 0.0% 0.0% 53.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Profit + -17 -275 -255 -13 8 8 -2 11 -10 -17 10 16 28
EPS in Rs -4 -70 -65 -4 2 2 -1 3 -3 -5 3 3 6
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 26 -46 -21 3 -18 42 -9 -12 -10 16 42 20 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 521 1,387 1,322 1,617 1,268 1,444 1,289 1,284 1,369 1,535
Expenses + 464 1,174 1,062 1,231 1,188 1,309 1,384 1,077 1,182 1,301
Operating Profit 57 213 260 386 81 134 -95 206 187 234
OPM % 11.0% 15.0% 20.0% 24.0% 6.0% 9.0% -7.0% 16.0% 14.0% 15.0%
Other Income + 2 12 27 29 16 22 -185 8 0 -2
Interest 25 82 78 84 75 90 105 115 95 89
Depreciation 34 83 94 109 112 111 103 99 100 105
Profit before tax 0 60 115 222 -91 -45 -488 1 -7 37
Tax % -70.0% 1.0% 0.0% 0.0% -36.0% -50.0% 16.0% 0.0% 0.0% —
Net Profit + 0 59 115 221 -58 -22 -567 1 -7 37
EPS in Rs — 21 39 57 -15 -6 -145 0 -2 7
Dividend Payout % 0.0% 22.0% 5.0% 11.0% 0.0% -49.0% 0.0% 0.0% 0.0% —
Sales growth — 166 -5 22 -22 14 -11 0 7 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 739 930 1,059 1,553 1,489 1,464 898 1,054 1,208 1,388
Borrowings + 633 538 722 621 1,037 1,013 1,012 796 687 591
Other Liabilities + 425 466 346 404 383 386 406 342 393 427
Total Liabilities 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,232 2,333 2,454
Fixed Assets + 1,086 1,218 1,397 1,382 1,356 1,364 1,268 1,193 1,238 1,201
CWIP 71 40 40 88 239 238 256 280 205 208
Investments 1 0 0 0 0 2 2 2 5 3
Other Assets + 663 701 716 1,144 1,350 1,295 825 757 886 1,043
Total Assets 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,232 2,333 2,454
Equity Capital 25 26 27 36 36 36 36 40 45 48

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 49 166 242 155 -242 156 109 213 153
Cash from Investing Activity + -85 -113 -359 -106 -243 -81 -4 -37 -99
Cash from Financing Activity + 68 -23 97 92 334 -113 -106 -180 -54
Net Cash Flow 31 30 -20 142 -151 -38 0 -4 1
Free Cash Flow 14 108 -25 -16 -451 46 69 173 101
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 92 85 103 49 -277 106 -113 104 83

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 30.49% → 41.93%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 51.14% 50.73% 45.89% 45.11% 44.92% 44.82% 41.1% 41.71% 42.37% 42.66% 42.79% 43.46%
Promoters 30.49% 30.49% 37.27% 37.27% 37.23% 37.94% 42.01% 42.01% 42.0% 42.0% 41.93% 41.93%
FII 16.62% 15.8% 14.0% 14.25% 14.67% 14.63% 14.25% 13.58% 11.98% 11.59% 11.52% 10.71%
DII 1.75% 2.97% 2.83% 3.37% 3.19% 2.61% 2.62% 2.69% 3.64% 3.75% 3.74% 3.89%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Solara Active Pha Sci Ltd (this stock) 3,347 70.7 2.33 -0.13%
Unichem Laboratories Ltd 3,511 29.5 1.26 3.17%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Shukra Pharmaceuticals L 3,639 82.1 30.56 28.9%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%
Hikal Limited 2,690 37.8 2.28 2.21%
Fredun Pharmaceuticals L 2,548 48.1 7.59 15.6%

Which Mutual Funds Hold Solara Active Pha Sci Ltd?

Frequently Asked Questions about Solara Active Pha Sci Ltd

Community Sentiment

What are other investors saying about Solara Active Pha Sci Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.